Zydus Lifesciences Gets USFDA Approval for Generic Arthritis Drug
Zydus Lifesciences receives USFDA approval to market Dexamethasone tablets (1mg) for arthritis, blood disorders, and other conditions in the US.
New Delhi, May 11 (PTI) Zydus Lifesciences on Saturday said it has received approval from the US health regulator to market a generic medication for arthritis and other conditions in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Dexamethasone tablets (1mg), the drug maker said in a statement.
Dexamethasone is used to treat conditions like arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer and immune system disorders.
As per IQVIA data, Dexamethasone tablets had an annual sales of USD 1.8 million in the US.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Dexamethasone tablets (1mg), the drug maker said in a statement.
Dexamethasone is used to treat conditions like arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer and immune system disorders.
As per IQVIA data, Dexamethasone tablets had an annual sales of USD 1.8 million in the US.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 7.07 (+ 5.37)
- 65169696
- Quasar India Ltd.
- 0.90 (+ 3.45)
- 48641740
- KBC Global
- 0.37 ( 0.00)
- 39296623
- Standard Capital
- 0.40 ( 0.00)
- 37430693
- YES Bank Ltd.
- 20.40 (+ 2.00)
- 36701123
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback